Infection requiring systemic antibiotic therapy or other serious infection within days before registration Active systemic infection requiring parenteral antibiotic therapy; all prior infections must have resolved following optimal therapy Active infection requiring systemic antibiotic therapy. Active infection requiring systemic antibiotic therapy Active systemic infection requiring parenteral antibiotic therapy. All prior infections must have resolved following optimal therapy Active infection requiring systemic antibiotic therapy. Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Patients who have an infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment are not eligible Subjects with active infection requiring antibiotic therapy Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Active infection requiring systemic antibiotic therapy Active infection requiring systemic antibiotic therapy. Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least days before beginning treatment Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Has an active infection requiring systemic antibiotic therapy at time of enrollment\r\n* Treatment with antibiotic prophylaxis for indwelling biliary stent(s) or peri-procedural antibiotics for uncomplicated biliary stent exchanges is allowed and not an exclusion Infection requiring intravenous antibiotic therapy or other serious infection within days before study enrollment Active infection requiring systemic antibiotic therapy Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least days before beginning treatment Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Infection requiring intravenous (IV) antibiotic therapy or other serious infection within days before randomization. Active infection requiring systemic antibiotic therapy. EXCLUSION - PARTICIPANT: Active infection requiring systemic antibiotic therapy. Participants requiring systemic antibiotics for infection must have completed therapy before treatment is initiated. Infection requiring systemic antibiotic therapy or other serious infection within days before study drug administration Must be free of systemic infection:\r\n* Subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection\r\n* Subjects on antibiotic therapy must be off antibiotics for at least days before beginning treatment Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy Infection requiring systemic intravenous antibiotic therapy or other serious infection within days before study enrollment Serious infection requiring parenteral antibiotic therapy or any other serious infection within days before randomization. Infection requiring intravenous antibiotic use within one week of enrollment. Subjects must not have a known active infection requiring intravenous antibiotic therapy Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment DONOR: Evidence of infection not responding to antibiotic therapy Systemic infection requiring intravenous (IV) antibiotic therapy =< days prior to registration Systemic infection requiring intravenous (IV) antibiotic therapy within days preceding the first dose of study drug, or other severe infection Active infection requiring intravenous (IV) antibiotic usage within the last week prior to study treatment Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment PHASE I: Patients should be free of active infection requiring antibiotic therapy (except for uncomplicated urinary tract infections) PHASE II: Patients should be free of active infection requiring antibiotic therapy (except for uncomplicated urinary tract infections) Has an active infection requiring intravenous antibiotic therapy Infection requiring systemic antibiotic therapy or other serious infection within days prior to start of study treatment Any antibiotic therapy or evidence of infection within week of registration Active infection requiring intravenous (IV) antibiotic usage within the last week prior to the dosimetry portion of the study Infection requiring systemic IV antibiotic therapy within days before cycle day of therapy Infection requiring current intravenous antibiotic therapy; the PI will serve as the final arbiter regarding eligibility Evidence of active infection requiring antibiotic therapy ? days prior to the first dose of PRTX- Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least days before beginning treatment Systemic infection requiring intravenous (IV) antibiotic therapy within days preceding the first dose of study drug, or other severe infection Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy before Screening is initiated Patients who have evidence of active infection that requires antibiotic therapy; patients must have been off antibiotic treatment for at least weeks prior to initiating treatment and must be confirmed to be clear of the infection; if patient develops an infection requiring antibiotic treatment while on the treatment portion of the study patients will be treated for the active infection with antibiotics and will resume vaccine treatment when the infection is healed Has an active infection requiring systemic therapy NOTE: Antibiotic therapy must have been completed a minimum of days prior to start of study treatment; Active systemic infection requiring parenteral antibiotic therapy Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment. Infection requiring intravenous antibiotic use within week. Concurrent serious infections (i.e., requiring an intravenous antibiotic) Infection requiring systemic antibiotic therapy within days prior to the start of study treatment Active infection requiring IV antibiotic usage within the last week prior to study treatment Infection requiring intravenous antibiotic use within week. Infection requiring systemic antibiotic therapy or other serious infection ? days prior to registration Has an active infection requiring systemic therapy; prior to dosing with REGN the subject must be at least half-lives from their last dose of antibiotic Evidence of ongoing or active infection requiring antibiotic therapy Active infection requiring systemic antibiotic therapy. Acute/chronic infections, open wounds, or any active infection requiring intravenous antibiotic therapy =< weeks prior to registration Any active infection requiring antibiotic therapy within weeks of study day . No active systemic infection requiring parenteral antibiotic therapy Systemic infection requiring IV antibiotic therapy within days preceding the first dose of study drug, or other severe infection Systemic infection requiring intravenous (IV) antibiotic therapy within days preceding the first dose of study drug, or other severe infection Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy Infection requiring systemic antibiotic therapy or other serious infection within days before first dose of study drug Serious infection requiring systemic antibiotic therapy within days prior to study treatment. An infection requiring antibiotic treatment within seven days of starting study treatment (day -) Active infection requiring systemic antibiotic therapy. Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy before Screening Active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment No active serious infections in particular if requiring systemic antibiotic or antimicrobial therapy Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Any infection requiring antibiotic or anti-viral treatment within weeks of screening Systemic infection requiring IV antibiotic therapy within days preceding the first dose of study drug, or other severe infection Systemic infection requiring intravenous (IV) antibiotic therapy within days preceding the first dose of study drug, or other severe infection Any infection requiring parenteral antibiotic therapy or causing fever (temperature > .F or .C) within week prior to registration Infection requiring intravenous (IV) antibiotic therapy or other serious infection within days before randomization. Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within days prior to the first dose of study treatment. Subjects with clinically serious infections requiring ongoing antibiotic therapy Active infection requiring systemic antibiotic therapy Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Any antibiotic therapy or evidence of infection within week of registration Must be free of systemic infection; subjects with active infections (whether or not they require antibiotic therapy) may be eligible after complete resolution of the infection; subjects on antibiotic therapy must be off antibiotics for at least days before beginning treatment Infection requiring systemic antibiotic therapy or other serious infection within days before randomization. Patients with active infection requiring systemic therapy or who are dependent on or currently receiving antibiotics that cannot be discontinued before dosing; (Note: subjects who discontinue an antibiotic prior to dosing must wait at least half-lives after the last dose of antibiotic before receiving any ADXS- infusion) Current infections requiring antibiotic therapy. Systemic infection requiring IV antibiotic therapy within days preceding the first dose of study drug, or other severe infection Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Concurrent serious infection requiring parenteral antibiotic therapy. Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment Known active infection requiring antibiotic treatment before the start of treatment (day ) Concurrent serious infections requiring parenteral antibiotic therapy. Subject has systemic infection requiring intravenous (IV) antibiotic therapy within days preceding the first dose of study drug, or other severe infection Serious infection requiring intravenous antibiotic therapy within days prior to study treatment Active systemic infection requiring systemic antibiotic treatment within hours prior to first dose of study treatment Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within days prior to the first dose of study treatment. Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within days prior to the first dose of study treatment. Receiving antibiotic therapy within days before the first dose of study treatment Infection requiring IV antibiotic therapy or other serious infection within days prior to first dose of study drug Systemic infection requiring IV antibiotic therapy within days preceding the first dose of study drug, or other severe infection Serious infection requiring treatment with systemically administered antibiotics at the time of study entrance, or an infection requiring systemic antibiotic therapy within days prior to the first dose of study treatment. For the HCC, HCC/BTC and BTC subgroups hepatitis C infection and hepatitis B infection if controlled with antiviral therapy are allowable. any infection requiring antibiotic, anticoagulant, or antiplatelet agents within the past weeks Active infection requiring antibiotic treatment Active infection requiring antibiotic therapy Systemic infection requiring intravenous (IV) antibiotic therapy within days preceding the first dose of study drug, or other severe infection Be receiving quinolone antibiotic therapy Systemic infection requiring IV antibiotic therapy or other serious infection within days before the first dose of study drug. Patients undergoing active antibiotic therapy Require antibiotic therapy prior to oral cleaning Patient is receiving antibiotic therapy for an active infection Known active infection requiring antibiotic treatment Infection requiring systemic antibiotic therapy within days prior to start of study treatment Active infection requiring systemic IV antibiotic therapy Infection requiring systemic antibiotic therapy or other serious infection within days before study enrollment have an active infection requiring antibiotic therapy, or concomitant malignancies Systemic infection requiring intravenous antibiotic therapy or other serious infection within days before the first dose of study drug.